Promising Growth Forecasts Leading to Analysts' Optimism for Procept Biorobotics (PRCT)
On December 12, UBS analyst Danielle Antalffy initiated coverage with a bullish rating on Procept Biorobotics Corp. (NASDAQ:PRCT). She rated the stock as a Buy and estimated a target price of $62.







